A London School of Hygiene and Tropical Medicine team revealed that women who are very underweight before they become pregnant are 72% more likely to miscarry in the first three months of pregnancy.
The chemical compound for the abortion pill has been found to prevent the growth of mammary tumors caused by the mutant gene responsible for a majority of breast and ovarian cancers, according to UC Irvine scientists.
Eighty-six percent of the recent decline in U.S. teen pregnancy rates is the result of improved contraceptive use, while a small proportion of the decline (14%) can be attributed to teens waiting longer to start having sex, according to a report by John Santelli, MD, MPH, department chair and professor of Clinical Population and Family Health at the Mailman School of Public Health and published in the January issue of the American Journal of Public Health.
The advisory committee of the American College of Obstetricians and Gynecologists confirms that the antidepressant Paxil (paroxetine) may cause fetal cardiac malformations. Obstetricians suggested to shun the antidepressants in pregnancy, if possible.
American Journal of Public Health study claims the declining teenage pregnancy rate in the US is down to better use of contraception rather than young people abstaining from sex.
Pregnant women who develop an infection of the placenta or nearby membranes in their first pregnancy have twice the risk of getting it in their second pregnancy, researchers at UT Southwestern Medical Center have found.
Pregnant smokers may “program” their children to become smokers, suggests research published in Tobacco Control.The authors base their findings on over 3,000 mothers and their children, who were part of a long term pregnancy study in Brisbane, Australia (MUSP) in 1981.
The teen birth rate in the United States fell to its lowest level ever in 2005, according to the latest birth statistics for the nation, released today by the Centers for Disease Control and Prevention (CDC).
Janssen-Ortho Inc., in consultation with Health Canada, wishes to highlight important new safety information pertaining to Evra. The Evra transdermal system marketed in Canada contains 6.0 mg norelgestromin (NGMN) and 0.60 mg ethinyl estradiol (EE) and is approved for use in contraception (prevention of pregnancy).
Monitoring fetal oxygen levels during labor does not lead to healthier newborns or reduce unnecessary Caesarean deliveries.